Human mesenchymal stem cell therapy in severe COVID-19 patients: 2-year follow-up results of a randomized, double-blind, placebo-controlled trialResearch in context

Human mesenchymal stem cell therapy in severe COVID-19 patients: 2-year follow-up results of a randomized, double-blind, placebo-controlled trialResearch in context

Summary: Background: Long-term effects of human mesenchymal stem cell (MSC) treatment on COVID-19 patients have not been fully characterized. The aim of this study was to evaluate the safety and efficacy of a MSC treatment administered to severe COVID-19 patients enrolled in our previous randomized...

Full description

Bibliographic Details
Main Authors: Tian-Tian Li, Bo Zhang, Hui Fang, Ming Shi, Wei-Qi Yao, Yuanyuan Li, Chao Zhang, Jinwen Song, Lei Huang, Zhe Xu, Xin Yuan, Jun-Liang Fu, Cheng Zhen, Yu Zhang, Ze-Rui Wang, Zi-Ying Zhang, Meng-Qi Yuan, Tengyun Dong, Ruidan Bai, Lulu Zhao, Jianming Cai, Jinghui Dong, Jianzeng Zhang, Wei-Fen Xie, Yonggang Li, Lei Shi, Fu-Sheng Wang
Format: Article
Language:English
Published: Elsevier 2023-06-01
Series:EBioMedicine
Subjects:
COVID-19
Mesenchymal stem cell
2-year follow-up
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396423001652

Internet

http://www.sciencedirect.com/science/article/pii/S2352396423001652

Similar Items